Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4783-4789

  Bak, S Peter ^a   Walters, Julie Jo ^a   Takeya, Motohiro ^b   Conejo Garcia, Jose R ^a   Berwin, Brent L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; SAPORIN; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR A ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEUKOPENIA; MACROPHAGE; MICROENVIRONMENT; MOUSE; NONHUMAN; OVARY TUMOR; PERITONEUM TUMOR; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ASCITES; CARRAGEENAN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTOXINS; LEUKOCYTES; MICE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SCAVENGER RECEPTORS, CLASS A;

EID: 34250327022     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4410     Document Type: Article

References (41)

1. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 2004;90: 2053-8.
2. Bronte V, Cingarlini S, Marigo I, et al. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest 2006;35: 327-57.
3. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
4. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
5. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006;95:272-81.
6. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006;35:459-83.
7. Serafini P, De Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72.
8. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
9. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21.
10. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196: 254-65.
11. Sandel MH, Dadabayev AR, Menon AG, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005;11: 2576-82.
12. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-26.
13. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004;10:950-8.
14. Conejo-Garcia JR, Buckanovich RJ, Benencia F, et al. Vascular leukocytes contribute to tumor vascularization. Blood 2005;105:679-81.
15. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91.
16. Berwin B, Delneste Y, Lovingood RV, Post SR, Pizzo SV. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J Biol Chem 2004;279:51250-7.
17. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci U S A 1993;90:3038-42.
18. Tomokiyo R, Jinnouchi K, Honda M, et al. Production, characterization, and interspecies reactivities of monoclonal antibodies against human class A macrophage scavenger receptors. Atherosclerosis 2002;161:123-32.
19. Sinha P, Clements VK, O strand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005;174:636-45.
20. Ishizaka S, Kuriyama S, Tsujii T. In vivo depletion of macrophages by desulfated iota-carrageenan in mice. J Immunol Methods 1989;124:17-24.
21. Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996;61: 109-12.
22. Mukhopadhyay S, Gordon S. The role of scavenger receptors in pathogen recognition and innate immunity. Immunobiology 2004;209:39-49.
23. Delneste Y, Magistrelli G, Gauchat J, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002;17:353-62.
24. Fraser I, Hughes D, Gordon S. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature 1993;364:343-6.
25. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
26. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 2005;92:1182-7.
27. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-7.
28. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13:1382-97.
29. + T cells. J Exp Med 2003;197: 1017-28.
30. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.
31. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006; 33:S3-11.
32. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107: 1399-410.
33. Thomson AW, Fowler EF. Carrageenan: a review of its effects on the immune system. Agents Actions 1981;11: 265-73.
34. Hamilton CA, Berek JS. Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol 2006;18:507-15.
35. Alberts DS, Markman M, Muggia F, et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancers. Gynecol Oncol 2006;103:783-92.
36. Amadori D, Sansoni E, Amadori A. Ovarian cancer: natural history and metastatic pattern. Front Biosci 1997;2:8-10.
37. Voss CY, Albertini MR, Maker JS. Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine. Transfus Med Rev 2004;18:189-202.
38. Liu SH, Zhang M, Zhang WG. Strategies of antigen-specific T-cell-based immunotherapy for cancer. Cancer Biother Radiopharm 2005;20:491-501.
39. Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res 2006;12: 1515-24.
40. Kryczek I, Zou L, Rodriguez P, et al. B7-4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-81.
41. + regulatory T cells in human ovarian carcinoma Cancer Res 2005;65:5020-6.